Yahoo Web Search

Search results

1. • Perceptive Advisors LLC Buys Shares of 3,436,600 CARGO Therapeutics, Inc. (NASDAQ:CRGX)

     ETF DAILY NEWS· 3 days ago

     Perceptive Advisors LLC purchased a new stake in shares of CARGO Therapeutics, Inc. (NASDAQ:CRGX – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities ...

2. • 

     Why lung cancer may be worse in nonsmokers — and more

     WGN Chicago via Yahoo News· 5 days ago

     Medical Watch Digest For June 13 Why lung cancer may be worse in nonsmokers Targeted treatment often...

3. • 

     Barinthus lays off 25% of staff, sidelines prostate cancer program to stretch out cash

     FierceBiotech· 6 days ago

     Barinthus Biotherapeutics has used positive interim data from a pair of phase 2 trials for its...

4. • 

     New data showcase promise, growing pains of CAR-T in autoimmune disease

     BioPharma Dive via Yahoo Finance· 2 days ago

     One expert described trial results presented at EULAR last week as “unprecedented.” But reports of...

5. • 

     Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment

     Zacks via Yahoo Finance· 2 days ago

     Amgen's (AMGN) Blincyto is now approved for the treatment of adult and pediatric patients one month...

6. • Lyell Immunopharma (NASDAQ:LYEL) Shares Down 8.9%

     ETF DAILY NEWS· 3 days ago

     Lyell Immunopharma, Inc. (NASDAQ:LYEL – Get Free Report) was down 8.9% during trading on Friday . The company traded as low as $2.35 and last traded at $2.36. Approximately 145,049 shares traded ...

7. • 

     GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the...

     NewMediaWire via Yahoo Finance· 16 hours ago

     10,000-participant randomized Phase 2b study will evaluate and compare GeoVax's multi-antigen,...

8. • 

     Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study

     Zacks via Yahoo Finance· 2 days ago

     Roche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory...

9. • ...STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or...

     Morningstar· 4 days ago

     Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma – The study met ...

10. • ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory...

      Morningstar· 5 days ago

      Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in patients with heavily pretreated relapsed ...